drugset / Trial / NCT01816230

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

NCT01816230

Phase 1/2 Completed 36 enrolled Gamida Cell ltd
NaSingle-groupOpen-labelTreatment

Summary

A Study Evaluating the Safety and Efficacy of Transplantation of a single cord blood unit (CBU) of NiCord®, umbilical cord blood-derived Ex Vivo Expanded Stem and Progenitor Cells in Patients with Hematological Malignancies.

Timeline

Start
2013-04
Primary completion
2017-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject omidubicel Cell therapy Other